

Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001

Deborah M. Stephens,¹ Hongli Li,² Louis S. Constine,³ Thomas J. Fitzgerald,⁴ John P. Leonard,⁵ Brad S. Kahl,⁶ Joo Y. Song,⁷ Michael L. LeBlanc,² Sonali M. Smith,⁸ Daniel O. Persky⁹ and Jonathan W. Friedberg¹⁰

¹Division of Hematology, University of Utah, Salt Lake City, UT; ²SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Departments of Radiation Oncology and Pediatrics, University of Rochester, Rochester, NY; ⁴Imaging and Radiation Oncology Core (IROC), Lincoln, RI; ⁵Division of Hematology and Medical Oncology, Weill Cornell Medical Center, New York, NY; ⁶Department of Medicine, Washington University School of Medicine, St. Louis, MO; ⁷Department of Pathology, City of Hope, Duarte, CA; ⁸Section of Hematology/Oncology, University of Chicago, Chicago, IL; ⁹Division of Hematology/Oncology, University of Arizona, Tucson, AZ and ¹⁰Division of Hematology/Oncology, University of Rochester, Rochester, NY, USA

Correspondence:

D. M. STEPHENS - Deborah.stephens@hci.utah.edu

<https://doi.org/10.3324/haematol.2022.281004>


Supplementary Data

Supplemental Table

Supplemental Table 1. 10-year Progression-Free Survival (PFS) and Overall Survival (OS) by Extranodal Site				
10-year Progression-Free Survival				
Extranodal Location	N	Events	10-year PFS	95% CI
Head and Neck	46	16	57%	(38% - 71%)
Thyroid	9	2	78%	(36% - 94%)
GI Track	11	4	67%	(28% - 88%)
Bone	13	3	70%	(30% - 90%)
Skin/Muscle/Soft Tissue	12	4	73%	(37% - 91%)
Breast	6	1	83%	(27% - 97%)
Other	7	0	100%	
10-year Overall Survival				
Extranodal Location	N	Events	10-year OS	95% CI
Head and Neck	46	12	75%	(58% - 86%)
Thyroid	9	1	89%	(43% - 98%)
GI Track	11	3	78%	(36% - 94%)
Bone	13	3	70%	(30% - 90%)
Skin/Muscle/Soft Tissue	12	4	63%	(17% - 88%)
Breast	6	1	83%	(27% - 97%)
Other	7	0	100%	

Supplemental Figures

Supplemental Figure 1. Consort Diagram for Included Patients



Supplemental Figure 1 Key

*Incorrect histology was: concurrent low-grade lymphoma (n=14), follicular lymphoma (n=5), primary mediastinal large cell lymphoma (n=3), mucosa-associated lymphoid tissue (n=2), B-cell lymphoma not otherwise specified (n=1), mantle cell lymphoma (n=1), primary cutaneous follicular center lymphoma (n=1), T-cell lymphoma (n=1)

⁺60 patients treated on S0014 received rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP) 3 cycles + involved field radiotherapy (IFRT) at doses from 2160-5400 centigray (cGy)

[^]43 patients treated on S0313 received RCHOP3 + IFRT (400-5000cGy) + Yttrium⁹⁰ ibritumomab tiuxetan (Y⁹⁰)

[#]112 patients treated on S1001 received RCHOP for 4 cycles, 7 patients received RCHOP for 3 cycles, 12 patients received RCHOP for 3 cycles + IFRT (4100-4500 cGy) + Y⁹⁰

Supplemental Figure 2. 10-year Progression-Free Survival (PFS, A) and Overall Survival (OS, B) in 135 Patients with Stage I Disease with Extranodal (red) versus Nodal (blue) Disease Presentation

